Compare AbCellera Biologics Inc (ABCL) vs Li Auto Inc (LI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Li Auto Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Li Auto Inc trades at $12.19 (market cap $11.78B). The key difference: Li Auto Inc is far larger — about 5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | LI | |
|---|---|---|
Market Cap | $2.35B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $31.80 |
52-Week Low | $2.78 | $11.74 |
Enterprise Value | $1.99B | $693.65M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Li Auto (LI) trades at $12.05, near its 52-week low, with a bearish technical outlook. Revenue declined to $112.31B in 2025, and net income fell to $1.12B, reflecting margin pressure. Analyst consensus is mixed with a $14.80 price target, but recent news highlights competitive headwinds and delivery growth of 30,895 vehicles in June 2026.
The stock faces near-term risks from intense EV competition and profitability challenges, but long-term recovery potential exists if L-series execution improves. Investors should weigh low valuation multiples against operational cash flow deficits and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
